What is claimed is:

1. A composition comprising a cyclooxygenase-2 inhibitor or a pharmaceutically acceptable salt of a cyclooxygenase-2 inhibitor and a topoisomerase II inhibitor or a pharmaceutically acceptable salt of a topoisomerase II inhibitor, wherein the cyclooxygenase-2 inhibitor or pharmaceutically acceptable salt of the cyclooxygenase-2 inhibitor is not a 2,3-substituted indole compound or a tetracyclic sulfonylbenzene compound.

2. A composition comprising:

a cyclooxygenase-2 inhibitor selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, meloxicam, parecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl-benzeneacetic acid, and (3Z)-3-[(4-chlorophenyl)[4-(methylsulfonyl)phenyl]methylene]dihydro-2(3H)-furanone; and

a topoisomerase II inhibitor selected from the group consisting of aclarubicin, amonafide, amrubicin, amsacrine, annamycin, 6,9-bis[(2-aminoethyl)amino]-benz[g]isoquinoline-5,10-dione, 1,11-dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, crisnatol, daunorubicin, doxorubicin, epirubicin, etoposide, galarubicin, idarubicin, iododoxorubicin, 10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl-α-D-galactopyranosyl)-3,4-O-[(S)-phenylmethylene]-β-D-galactopyranosyl]oxy]-5,12-dihydro-1-methyl-5,12-dioxobenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-6-yl ester-3-ethoxy-propanoic acid, 8-ethyl-7,8,9,10-tetrahydro-

1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione, (7S,9S)-7-[[4-O-(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)-2,6-dideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-5,12-naphthacenedione, merbarone, mitoxantrone, nemorubicin, pirarubicin, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, sobuzoxane, teniposide, and valrubicin.

3. The composition of claim 1 or 2 wherein the cyclooxygenase-2 selective inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, meloxicam, and parecoxib and the topoisomerase II inhibitor is selected from the group consisting of aclarubicin, amonafide, amrubicin, amsacrine, cristnatol, daunorubicin, doxorubicin, epirubicin, etoposide, idarubicin, mitoxantrone, nemorubicin, pirarubicin, sobuzoxane, teniposide, and valrubicin.

4. A composition comprising celecoxib and a topoisomerase II inhibitor.

5. The composition of any of claims 1, 2, 3, or 4 wherein the topoisomerase II inhibitor is epirubicin or idarubicin.

6. A method for treating a neoplasia or a neoplasia related disorder in a mammal in need of such treatment, the method comprising administering to the mammal a therapeutically effective amount of a cyclooxygenase-2 inhibitor or a pharmaceutically acceptable salt of a cyclooxygenase-2 inhibitor and a therapeutically effective amount of a topoisomerase II inhibitor or a pharmaceutically acceptable salt of a topoisomerase II inhibitor, wherein the

cyclooxygenase-2 inhibitor or pharmaceutically acceptable salt of the cyclooxygenase-2 inhibitor is not a 2,3-substituted indole compound or a tetracyclic sulfonylbenzene compound.

7. A method for treating a neoplasia or a neoplasia related disorder in a mammal in need of such treatment, the method comprising administering to the mammal a therapeutically effective amount of a cyclooxygenase-2 inhibitor selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, meloxicam, parecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, 2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl-benzeneacetic acid, and (3Z)-3-[(4-chlorophenyl)[4-(methylsulfonyl)phenyl]methylene]dihydro-2(3H)-furanone; and

a topoisomerase II inhibitor selected from the group consisting of aclarubicin, amonafide, amrubicin, amsacrine, annamycin, 6,9-bis[(2-aminoethyl)amino]-benz[g]isoquinoline-5,10-dione, 1,11-dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, crisnatol, daunorubicin, doxorubicin, epirubicin, etoposide, galarubicin, idarubicin, iododoxorubicin, 10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl-α-D-galactopyranosyl)-3,4-O-[(S)-phenylmethylene]-β-D-galactopyranosyl]oxy]-5,12-dihydro-1-methyl-5,12-dioxobenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-6-yl ester-3-ethoxy-propanoic acid, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione, (7S,9S)-7-[[4-O-(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)-2,6-

dideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-5,12-naphthacenedione, merbarone, mitoxantrone, nemorubicin, pirarubicin, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, sobuzoxane, teniposide, and valrubicin.

8. The method of claim 6 or 7 wherein the cyclooxygenase-2 selective inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, meloxicam, and parecoxib and the topoisomerase II inhibitor is selected from the group consisting of aclarubicin, amonafide, amrubicin, amsacrine, cristnatol, daunorubicin, doxorubicin, epirubicin, etoposide, idarubicin, mitoxantrone, nemorubicin, pirarubicin, sobuzoxane, teniposide, and valrubicin.

9. A method for treating a neoplasia or a neoplasia related disorder in a mammal in need of such treatment, the method comprising administering to the mammal a therapeutically effective amount of celecoxib and a topoisomerase II inhibitor.

10. The method of any of claims 6, 7, 8, or 9 wherein the topoisomerase II inhibitor is epirubicin or idarubicin.

11. The method of any of claims 6, 7, 8, 9, or 10 wherein the neoplasia or neoplasia related disorder is selected from the group consisting of a malignant tumor growth selected from the group consisting of acral lentiginous melanoma, actinic keratoses, acute lymphocytic leukemia, acute myeloid leukemia, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, anal canal cancer, anal cancer, anorectum cancer, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, biliary cancer, bone cancer, bone marrow cancer, brain cancer, breast

cancer, bronchial cancer, bronchial gland carcinomas, carcinoids, carcinoma, carcinosarcoma, cholangiocarcinoma, chondosarcoma, choriod plexus papilloma/carcinoma, chronic lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, colon cancer, colorectal cancer, connective tissue cancer, cystadenoma, digestive system cancer, duodenum cancer, endocrine system cancer, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell cancer, ependymal cancer, epithelial cell cancer, esophageal cancer, Ewing's sarcoma, eye and orbit cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric antrum cancer, gastric fundus cancer, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, heart cancer, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatobiliary cancer, hepatocellular carcinoma, Hodgkin's disease, ileum cancer, insulinoma, intaepithelial neoplasia, interepithelial squamous cell neoplasia, intrahepatic bile duct cancer, invasive squamous cell carcinoma, jejunum cancer, joint cancer, Kaposi's sarcoma, kidney and renal pelvic cancer, large cell carcinoma, large intestine cancer, larynx cancer, leiomyosarcoma, lentigo maligna melanomas, leukemia, liver cancer, lung cancer, lymphoma, male genital cancer, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal cancer, mesothelial cancer, metastatic carcinoma, mouth cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal tract cancer, nervous system cancer, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, non-epithelial skin cancer, non-Hodgkin's lymphoma, oat cell carcinoma, oligodendroglial cancer, oral cavity cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillary serous adenocarcinoma, penile cancer, pharynx cancer, pituitary tumors, plasmacytoma, prostate cancer,

pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory system cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, smooth muscle cancer, soft tissue cancer, somatostatin-secreting tumor, spine cancer, squamous cell carcinoma, stomach cancer, striated muscle cancer, submesothelial cancer, superficial spreading melanoma, T cell leukemia, testicular cancer, thyroid cancer, tongue cancer, undifferentiated carcinoma, ureter cancer, urethra cancer, urinary bladder cancer, urinary system cancer, uterine cervix cancer, uterine corpus cancer, uveal melanoma, vaginal cancer, verrucous carcinoma, VIPoma, vulva cancer, well differentiated carcinoma, and Wilms tumor.

12. The method of any of claims 6, 7, 8, 9, or 10 wherein the neoplasia or neoplasia related disorder is selected from the group consisting of lung cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, ovary cancer, cervical cancer, gastrointestinal cancer, and leukemia.

13. The method of any of claims 6, 7, 8, 9, or 10 wherein the neoplasia or neoplasia related disorder is selected from the group consisting of lung cancer, colorectal cancer, breast cancer, prostate cancer, bladder cancer, ovary cancer, and central nervous system cancer.